preview

The Epipen's Ethical Case

Decent Essays

Mylan is a company that is most widely known for their delivery system of epinephrine, an adrenaline that aids in moderate to severe allergic reactions. Most recently, the company has seen their name in the headlines because of the actions that they have taken. Most notably, the 400% increase in the price of their product, dubbed Epipen. Their chief executive officer, Heather Bresch has received most of the backlash because of her questionable decision making. Under the ethics of care and Rawls theory of justice, Mylan and its CEO are engaged in unethical business dealings. The ethic of care can be defined as, “an act motivated by an apprehension of the cared-for’s reality, a receiving of the cared-for into the one-caring such that the one-caring …show more content…

One of these groups is the consumer. The company is consistently raising prices of the Epipens which is making it increasingly difficult for consumers to be able to pay premium prices for the medicine. The Epipen has a shelf life of twelve to eighteen months, meaning that the consumer has to constantly replace expired and unused Epipens. This is violating the ethic of care because Mylan has a responsibility to the consumer to provide fair and reasonable prices for their product. Bresch shows a lack of sympathy when she is trying shift the blame from her company and pass the responsibility off to the insurance companies (Thomas, …show more content…

Continuing with the article by Thomas, Bresch had “angered” investors when Mylan moved its headquarters from America to the Netherlands. It was also noted that Mylan used laws in it’s new location to blocked a favorable take over by another pharmaceutical company. It is the duty and obligation of Mylan, Bresch in particular, to satisfy the shareholders. A quote from class 6 stated, “[Y]ou can and should try to create friends at your company, because underneath friendship is this concept of trust and respect” (Bryant, 2015). There is an inherent trust when a person becomes a shareholder. The way that Bresch treated the shareholders would be grounds to retract that trust and in some investors eye, respect. Bresch should have informed shareholders of the move to the Netherlands for the simple fact that it is a move that affects their investment. It was no guarantee that the company would thrive in a foreign country so she put their money at risk without their input or approval. In addition to the move, Thomas’ article stated that many investors favored a takeover by another large pharmaceutical which was conveniently deflected because of Dutch law. This is also playing with the money of the people that Bresch is obligated to care for. Investors must have seen advantages to being taken over by another company but were upset when they learned that the potential buy out was

Get Access